EP0802791A1 - 3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds - Google Patents
3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compoundsInfo
- Publication number
- EP0802791A1 EP0802791A1 EP95943974A EP95943974A EP0802791A1 EP 0802791 A1 EP0802791 A1 EP 0802791A1 EP 95943974 A EP95943974 A EP 95943974A EP 95943974 A EP95943974 A EP 95943974A EP 0802791 A1 EP0802791 A1 EP 0802791A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- independently
- alkyl
- cr4r5
- substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention relates to novel 3,3-(disubstituted)cyclohexan-l-ylidine acetate dimers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
- TNF Tumor Necrosis Factor
- Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.
- Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29, 1973].
- adenylate cyclase is activated, which converts Mg + 2-ATP to cAMP at an accelerated rate.
- Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma.
- cAMP cyclic nucleotide phosphodiesterases
- PDE isozyme
- PDE IV is responsible for cAMP breakdown in airway smooth muscle and inflammatory cells.
- Talphy "Phosphodiesterase Isozymes: Potential Targets for Novel Anti-asthmatic Agents” in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd., 1989]. Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils.
- PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo.
- PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated.
- Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
- TNF Tumor Necrosis Factor
- rheumatoid arthritis rheumatoid spondylitis
- osteoarthritis gouty arthritis and other arthritic conditions
- sepsis septic shock, endotoxic shock, gram negative sepsis
- toxic shock syndrome adult respiratory distress syndrome
- cerebral malaria chronic pulmonary inflammatory disease
- silicosis pulmonary sarcoidosis
- bone resorption diseases reperfusion injury, graft vs.
- allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis.
- AIDS acquired immune deficiency syndrome
- AIDS AIDS
- ARC AIDS related complex
- keloid formation scar tissue formation
- Crohn's disease Crohn's disease
- ulcerative colitis ulcerative colitis
- pyresis in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis.
- HIV Human Immunodeficiency Virus
- HIV-1 HIV-1
- HIV-2 HIV-2
- HIV-3 HIV-3
- HIV entry into the T lymphocyte requires T lymphocyte activation.
- Viruses such as HIV-l or HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HIV replication.
- Cytokines are implicated in activated T-cell-mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HIV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HIV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HIV infection.
- Monocytes, macrophages, and related cells such as kupffer and glial cells, have also been implicated in maintenance of the HIV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells.
- TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted.
- CMV cytomegalovirus
- influenza virus influenza virus
- adenovirus adenovirus
- herpes virus herpes virus
- TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al, Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al. Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al, Antimicrobial Agents and Chemotherapy, 35, (10): 2046-48, 1991 ; and Luke et al, Journal of Infectious Diseases, 162:21 1-214,1990].
- Ri is independently -(CR4R5) n C(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5)nO(CR4R5)mR6, or -(CR4R5)r 6 wherein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6;
- R4 and R5 are independently selected hydrogen or Ci-2 alkyl
- R6 is independently hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetiahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4- 6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R ⁇ is hydroxyl, then
- X is independently YR2, fluorine, NR4R5, or formyl amine
- Y is independently O or S(O) m '; m' is O, l , or 2;
- X2 is independently O or NR8;
- X3 is hydrogen or X;
- X4 is H, R9, OR8, CN, C(O)R8, C(O)OR8, C(O)NRsR8, or NR ⁇ R ⁇ :
- R2 is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4;
- W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms;
- Z is independently C(-CN)2, CR14CN, CRi4C(O)ORs, CR * 4C(O)NR8Rl4, C(-CN)NO2, C(-CN)C(O)OR9, C(-CN)OC(O)R9, C(-CN)OR9, or C(-CN)C ( O)NR8Rl4;
- Y' is independently O or S;
- R7 is independently -(CR4R5)qRi2 or Cj.g alkyl wherein the R12 or Cj.g alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NRJQ I 1 - -C(O)R ⁇ , -CO2R8.
- Rl2 is independently R13, C3-C7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyrrolyl, piperazinyl, piperidinyl, mo holinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, or phenyl;
- R is independently selected from hydrogen or R9;
- R9 is independently C* _4 alkyl optionally substituted by one to three fluorines;
- R* 0 is independently OR8 or R] ;
- Rj 1 is independently hydrogen, or C j _4 alkyl unsubstituted or substituted by one to three fluorines; or when Rio and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S;
- Rl3 is independently oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C ⁇ _2 alkyl groups;
- Rj4 is independently hydrogen or R7; or when R8 and R]4 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; or the pharmaceutically acceptable salts thereof.
- This invention also relates to the pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.
- the invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE IV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) as shown below.
- the invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).
- the invention also provides a method for the treatment of asthma which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).
- This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I).
- This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto.
- This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HIV), which comprises administering to such human an effective TNF inhibiting amount of a compound of Formula (I).
- HAV human immunodeficiency virus
- Compounds of Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.
- compounds of Formula (I) are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
- This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE IV in a mammal in need thereof and to inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).
- Phosphodiesterase IV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis. Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
- PDE IV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infarct dementia.
- viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (I).
- viruses include, but are not limited to HIV- 1, HIV-2 and HIV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex.
- CMV cytomegalovirus
- influenza influenza
- adenovirus adenovirus
- Herpes group of viruses such as, but not limited to, Herpes zoster and Herpes simplex.
- This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HIV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I).
- HAV human immunodeficiency virus
- TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
- viruses include, but are not limited to feline immunodeficiency virus (FTV) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.
- FTV feline immunodeficiency virus
- retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.
- the compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
- a preferred disease state for treatment is fungal meningitis.
- the compounds of Formula (I) may be administered in conjunction with other drugs of choice for systemic yeast and fungal infections.
- Drugs of choice for fungal infections include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B.
- polymixins such as Polymycin B
- imidazoles such as clotrimazole, econazole, miconazole, and ketoconazole
- triazoles such as fluconazole, and itranazole
- Amphotericins in particular Amphotericin B and liposomal Amphotericin B.
- the compounds of Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) to a mammal in need of such treatment.
- a compound of Formula (I) is administered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B.
- C* _ 3 alkyl C ⁇ _ 4 alkyl
- C]_ 6 alkyl or “alkyl” groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl. n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
- Alkenyl means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1- propenyl, 2-propenyl, 2-propynyl, or 3-methyl-2-propenyl.
- cycloalkyl or “cycloalkyl alkyl” means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl.
- Aryl or “aralkyl”, unless specified otherwise, means an aromatic ring or ring system of 6- 10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl.
- the aryl is monocyclic, i.e, phenyl.
- the alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms.
- Heteroaryl means an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl.
- Halo means all halogens, i.e., chloro, fluoro, bromo, or iodo.
- “Inhibiting the production of IL-1” or “inhibiting the production of TNF” means: a) a decrease of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of IL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL- 1 or TNF levels as a postranslational event.
- TNF mediated disease or disease states means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL-6.
- TNF- ⁇ also known as lymphotoxin
- TNF- ⁇ also known as cachectin
- TNF- ⁇ also known as cachectin
- both TNF- ⁇ and TNF- ⁇ are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF” unless specifically delineated otherwise.
- TNF- ⁇ is inhibited.
- Cytokine means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses.
- a cytokine includes, but is not limited to, monokines and lyrnphokines regardless of which cells produce them.
- the cytokine inhibited by the present invention for use in the treatment of a HIV- infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HIV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.
- this cytokine is TNF- ⁇ .
- All of the compounds of Formula (I) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE IV and in treatment of disease states mediated thereby.
- Preferred compounds are as follows: When R ⁇ for the compounds of Formula (I) is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a C i .4 alkyl substituted by 1 or more fluorines.
- the preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, - CHF2, -CF2CHF2, -CH2CF3, and -CH2CHF2.
- Rj substitutents for the compounds of Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl with or without an hydroxyl group on the ring, C7- 11 polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or C ⁇ -2 alkyl unsubstituted or substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2)0-2CH3, -(CH2)1-3O(CH2)0-2CH 3 , and -(CH2)2-4OH.
- the R4 and R5 terms are independently hydrogen or alkyl.
- the individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can unsubstituted or be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above.
- Ri is a C7-I 1 polycycloalkyl
- examples are bicyclo[2.2.1]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo[5.2.1.0 2 ⁇ 6 ]decyl, etc. additional examples of which are described in Saccamano et al, WO 87/06576, published 5 November 1987, whose disclosure is incorporated herein by reference in its entirety.
- Preferred Z terms are C(-CN)2, CRHC(O)OR8, CRi4C(O)NRsRl4, C(-CN)C(O)OR9, C(-CN)OC(O)R9, C(-CN)OR9, or C(-CN)C(O)NR8Rl4;
- Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen.
- the preferred X2 group for Formula (I) is that wherein X2 is oxygen.
- the preferred X3 group for Formula (I) is that wherein X3 is hydrogen.
- Preferred R2 groups, where applicable, is a Ci-2 alkyl unsubstituted or substituted by 1 or more halogens.
- the halogen atoms are preferably fluorine and chlorine, more preferably fluorine.
- More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a C]-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are the -CHF2 and -CH3 moieties.
- W is preferably alkyl. alkenyl or alkynyl of 2 to 4 carbon atoms, and where it is alkenyl or alkynyl, that one or two double or triple bonds be present. It is most preferred that W be 1,3-butadiynyl.
- R7 moieties include unsubstituted or substituted -(CH2)l- 2(cyclopropyl), -(CH2)0-2(cyclobutyl), -(CH2)0-2(cyclopentyl), -(CH2)0- 2(cyclohexyl), -(CH2)0-2(2-, 3- or 4-pyridyl), (CH2)l-2(2-imidazolyl), (CH2)2(4- mo ⁇ holinyl), (CH2)2(4-piperazinyl), (CH2)l-2(2-thienyl), (CH2)l-2(4-thiazolyl), and (CH2)0-2phenyl;
- Preferred rings when Rio and Rl l in the moiety -NRifjRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring unsubstituted or containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 2-(R ⁇ )-l -imidazolyl, 1 -pyrazolyl, 3-(R ⁇ )-l -pyrazolyl, 1- triazolyl, 2-triazolyl, 5-(Rs)-l -triazolyl, 5-(R8)-2-triazolyl, 5-(R ⁇ )-l -tetrazolyl, 5-(R8)-2-tetrazolyl, 1 -tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(Rs)- l- piperazinyl, or pyrrolyl ring.
- Preferred rings when Rs and R14 in the moiety -NR ⁇ Rl4 together with the nitrogen to which they are attached may form a 5 to 7 membered ring unsubstituted or containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 1-pyrazolyl, 1 -triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl, mo ⁇ holinyl, piperazinyl, and pyrrolyl.
- the respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I).
- Illustrations of such carbon substitutions includes, but is not limited to, 2-(R7)-l -imidazolyl, 4-(R7)-l -imidazolyl, 5-(R7)-l -imidazolyl, 3-(R7)-l -pyrazolyl, 4-(R7)-l -pyrazolyl, 5-(R7)-l -pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)-l -triazolyl, 5-(R7)-l -triazolyl, 5-(R7)-l -tetrazolyl, and 5-(R7)-2-tetrazolyl.
- R7 includes, but is not limited to, l-(R7)-2-tetrazolyl, 2-(R7)-l -tetrazolyl, 4-(R7)- l - piperazinyl. Where applicable, the ring may be substituted one or more times by R7.
- Preferred groups for NRsRl4 which contain a heterocyclic ring are 5-(Ri4)- 1 - tetrazolyl, 2-(Rj 4)- 1 -imidazolyl, 5-(Ri4)-2-tetrazolyl, 4-(Ri 4)- 1 -piperazinyl, or 4-(R 15)- 1 -piperazinyl.
- Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[ 1,2,3]), (3- or 5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[l,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl).
- the heterocyclic ring itself may be unsubstituted or substituted by Rs either on an available nitrogen or carbon atom, such as l-(R8)-2-imidazolyl, l-(R8)-4-imidazolyl, l-(R8)-5-imidazolyl, l-(R8)-3-pyrazolyl, l-(R8)-4-pyrazolyl, l-(R8)-5-pyrazolyl, 1 -(R8)-4-triazolyl, or l-(R8)-5-triazolyl.
- the ring may be substituted one or more times by
- Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF2H
- W is 1,3- butadiynyl
- X is YR2
- Y is oxygen
- X2 is oxygen
- X3 is hydrogen
- R2 is CF2H or methyl.
- salts of the instant compounds where they can be prepared, are also intended to be covered by this invention. These salts will be ones which are acceptable in their application to a pharmaceutical use. By that it is meant that the salt will retain the biological activity of the parent compound and the salt will not have untoward or deleterious effects in its application and use in treating diseases.
- compositions are prepared in a standard manner.
- the parent compound dissolved in a suitable solvent, is treated with an excess of an organic or inorganic acid, in the case of acid addition salts of a base, or an excess of organic or inorganic base where the molecule contains a COOH for example.
- compositions of the present invention comprise a pharmaceutical carrier or diluent and some amount of a compound of the formula (I).
- the compound may be present in an amount to effect a physiological response, or it may be present in a lesser amount such that the user will need to take two or more units of the composition to effect the treatment intended.
- These compositions may be made up as a solid, liquid or in a gaseous form. Or one of these three forms may be transformed to another at the time of being administered such as when a solid is delivered by aerosol means, or when a liquid is delivered as a spray or aerosol.
- the nature of the composition and the pharmaceutical carrier or diluent will, of course, depend upon the intended route of administration, for example parenterally, topically, orally or by inhalation.
- the pharmaceutical composition will be in the form of a cream, ointment, liniment, lotion, pastes, aerosols, and drops suitable for administration to the skin, eye, ear, or nose.
- the pharmaceutical composition will be in the form of a sterile injectable liquid such as an ampule or an aqueous or non-aqueous liquid suspension.
- a sterile injectable liquid such as an ampule or an aqueous or non-aqueous liquid suspension.
- the pharmaceutical composition will be in the form of a tablet, capsule, powder, pellet, atroche, lozenge, syrup, liquid, or emulsion.
- examples of appropriate pharmaceutical carriers or diluents include: for aqueous systems, water; for non-aqueous systems, ethanol, glycerin, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, liquid parafins and mixtures thereof with water; for solid systems, lactose, kaolin and mannitol; and for aerosol systems, dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide.
- the instant compositions may include other ingredients such as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers and the like, provided that the additional ingredients do not have a detrimental effect on the therapeutic action of the instant compositions.
- the amount of carrier or diluent will vary but preferably will be the major proportion of a suspension or solution of the active ingredient.
- the diluent is a solid it may be present in lesser, equal or greater amounts than the solid active ingredient.
- a compound of formula I is administered to a subject in a composition comprising a nontoxic amount sufficient to produce an inhibition of the symptoms of a disease in which leukotrienes are a factor.
- Topical formulations will contain between about 0.01 to 5.0% by weight of the active ingredient and will be applied as required as a preventative or curative agent to the affected area.
- the dosage of the composition is selected from the range of from 50 mg to 1000 mg of active ingredient for each administration.
- equal doses will be administered 1 to 5 times daily with the daily dosage regimen being selected from about 50 mg to about 5000 mg. No unacceptable toxicological effects are expected when these compounds are administered in accordance with the present invention.
- Compounds of Formula (I), wherein W is a 1,3-butadiyne and wherein A and B represent Z as defined in relation to Formula (I) or a group convertible to Z, may be prepared by the processes disclosed herein which comprise, for example, coupling of a molecule of the Formula 1 -Scheme 1 with a molecule of the Formula 2-Scheme 1 using an appropriate metal salt, such as cupric acetate, in a suitable solvent, such as DMF or pyridine, or a combination, such as pyridine/methanol/water, as in the method of Eglington and Galbraith (J. Chem. Soc, 1959, 889), to provide a compound of the Formula 3-Scheme 1.
- an appropriate metal salt such as cupric acetate
- a suitable solvent such as DMF or pyridine
- a combination such as pyridine/methanol/water
- the intermediate compounds represented by Formula 1- or 2-Scheme 1 may be prepared by the following prodecures: a) For those intermediates wherein X and X3 are other than Br, I, NO2, amine, formyl amine, or S(O)m' when m' is 1 or 2. reacting a compound of Formula (A)
- Rj represents Rj as defined in relation to Formula (I) or a group convertable to Rj and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 and X4 is a counter ion (e.g., lithium, magnesium, etc.) with a compound of the Formula (B)
- a counter ion e.g., lithium, magnesium, etc.
- X5 is, e.g., OCH3, OC2H5, OCH(CH3)2, etc., followed by appropriate workup to provide a compound of Formula (C)
- Rj represents Ri as defined in relation to Formula (I) or a group convertable to Ri and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 (see the PCT patent application WO 9115-451 -A).
- Michael-type reaction of such a compound of the Formula (4) with the appropriate precursor of R3 then provides a compound of the Formula ( 1 ); for example, use of diethylaluminum cyanide provides a compound of the Formula (1) wherein Ri represents Ri as defined in relation to Formula (I) or a group convertable to Ri and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 and the 3- position on the cyclohexyl ring is substituted by CN.
- R3 is CHO and Z is O may be prepared from compounds having the CN at the 3- position and Z is O after appropriate protection of the ketone as, e.g., a ketal, followed by reduction of the CN moiety with, e.g., di- isobutylaluminum hydride, followed by appropriate workup.
- the acetylene group is obtained by protecting the carbonyl group (Z) as a ketal by reacting the ketal with a mixture of dimethyl (diazomethyl)phosphonate and potassium r-butoxide or other suitable base, in an inert solvent, such as tetrahydrofuran, at reduced temperature, followed by appropriate workup and ketone deprotection to provide the intermediates of 1 -Scheme- 1 and 1 -Scheme- 1.
- Reducing a compound of Formula (I), wherein W is a 1,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z to a compound of the Formula (I) wherein W is a fully saturated hydrocarbon chain (i.e., n-butyl) may be accomplished using, e.g., palladium metal according to the method of Tedeschi (J. Org. Chem., 1962, 27, 2398), or, e.g., platinum oxide according to the method of Jutz (Ber., 1958, 91, 1867) or that of Suzuki and Kurosawa (Chem. Lett., 1980, 1177).
- Reducting a compound of Formula (I), wherein W is a 1 ,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z, to provide a compound of the Formula (I) wherein W is a 1,3-butadiene may be accomplished using, e.g., the hydroboration-protonolysis procedure of Zweifel and Polston (J. Am. Chem. Soc, 1970, 92, 4068), or, e.g., the hydroalumination-protonolysis procedure of Zweifel et al. (Synthesis, 1977, 52).
- the Z groups may require protection during the coupling and/or reductive steps described herein as, e.g., a dimethyl ketal or 2-(l,3-dioxolane), followed by deprotection and then further treatment.
- compounds of the Formula (I), wherein W represent W and Z' as defined in relation to Formula (I) or a group convertible to W may be prepared from the corresponding ketones as, e.g., compound 1 -Scheme 2. by the synthetic procedures described in United States patent application 08/130,215 filed 10 October 1993. Syntheses of such ketone starting materials are described in a co-pending U.S. application filed on even day herewith by at least one of the inventors, both of which are assigned to a common assignee.
- inhibitory effect of compounds of Formula (I) on in vitro TNF production by human monocytes may be determined by the protocol as described in Badger et al,
- Example 1 demonstrated a positive in vivo response in reducing serum levels of TNF induced by the injection of endotoxin.
- Formula (I) can be determined using a battery of five distinct PDE isozymes.
- the tissues used as sources of the different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE Ic, guinea-pig heart; 3) PDE III, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "la"), canine trachealis.
- PDEs la, lb, Ic and III are partially purified using standard chromatographic techniques [To ⁇ hy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990].
- PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography [To ⁇ hy et al, J. Biol. Chem., 267: 1798-1804, 1992].
- Phosphodiesterase activity is assayed as described in the protocol of To ⁇ hy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive ICso's in the nanomolar to ⁇ M range for compounds of the workings examples described herein for Formula (I) have been demonstrated.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36366694A | 1994-12-23 | 1994-12-23 | |
US363666 | 1994-12-23 | ||
PCT/US1995/016841 WO1996019985A1 (en) | 1994-12-23 | 1995-12-21 | 3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0802791A1 true EP0802791A1 (en) | 1997-10-29 |
EP0802791A4 EP0802791A4 (en) | 1998-03-25 |
Family
ID=23431171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95943974A Withdrawn EP0802791A4 (en) | 1994-12-23 | 1995-12-21 | 3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0802791A4 (en) |
JP (1) | JPH10511665A (en) |
WO (1) | WO1996019985A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019748A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
WO1996020159A1 (en) * | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds |
-
1995
- 1995-12-21 EP EP95943974A patent/EP0802791A4/en not_active Withdrawn
- 1995-12-21 JP JP8520567A patent/JPH10511665A/en active Pending
- 1995-12-21 WO PCT/US1995/016841 patent/WO1996019985A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019748A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
WO1996020159A1 (en) * | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds |
WO1996020690A2 (en) * | 1994-12-23 | 1996-07-11 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds |
Non-Patent Citations (1)
Title |
---|
See also references of WO9619985A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPH10511665A (en) | 1998-11-10 |
WO1996019985A1 (en) | 1996-07-04 |
EP0802791A4 (en) | 1998-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5723681A (en) | 3,3-(disubstituted)cyclohexan-1-01 dimers and related compounds | |
US5767151A (en) | 3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and related compounds | |
US5990119A (en) | 1,4,4-(trisubstituted)cyclohexane monomers and related compounds | |
US5646158A (en) | 1,3,3-(trisubstituted)cyclohex-1-ene monomers and related compounds | |
WO1996020160A1 (en) | 1,3,3-(trisubstituted)cyclohexane dimers and related compounds | |
NZ300524A (en) | 3,3-(disubstituted)cyclohexan-1-ol derivatives, medicaments and treatment of asthma | |
WO1996020159A1 (en) | 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds | |
WO1996019984A1 (en) | 4,4-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds | |
EP0799205B1 (en) | 1,4,4-(trisubstituted)cyclohex-1-ene derivatives as pde iv- and tnf-inhibitors | |
WO1996019985A1 (en) | 3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds | |
EP0799031A1 (en) | 1,4,4-(trisubstituted)cyclohexane dimers and related compounds | |
WO1996020153A1 (en) | 4,4-(disubstituted)cyclohexan-1-one dimers and related compounds | |
EP0794773A1 (en) | 1,4,4-(trisubstituted)cyclohexane monomers and related compounds | |
WO1996020174A1 (en) | 1,3,3-(trisubstituted)cyclohexane monomers and related compounds | |
WO1996020156A1 (en) | 3,3-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds | |
EP0801566A1 (en) | 4,4-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds | |
WO1999052848A1 (en) | Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds | |
WO1996019994A1 (en) | 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds | |
EP0796092A1 (en) | 3,3-(disubstituted)cyclohexan-1-one dimers and related compounds | |
EP0799184A1 (en) | 4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds | |
EP0841908A1 (en) | 1,3,3-(trisubstituted)cyclohex-1-ene dimers and related compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970717 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE DK FR GB IT LI NL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980206 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE DK FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19980703 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19981114 |